Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.
Varewijck, A J
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. [electronic resource] - Diabetologia Apr 2012 - 1186-94 p. digital
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
1432-0428
10.1007/s00125-011-2435-7 doi
Blood Glucose--metabolism
Diabetes Mellitus, Type 2--blood
Drug Therapy, Combination
Female
Glycated Hemoglobin--metabolism
Humans
Hypoglycemic Agents--therapeutic use
Insulin Glargine
Insulin, Isophane--therapeutic use
Insulin, Long-Acting--therapeutic use
Insulin-Like Growth Factor I--metabolism
Male
Metformin--therapeutic use
Middle Aged
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. [electronic resource] - Diabetologia Apr 2012 - 1186-94 p. digital
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
1432-0428
10.1007/s00125-011-2435-7 doi
Blood Glucose--metabolism
Diabetes Mellitus, Type 2--blood
Drug Therapy, Combination
Female
Glycated Hemoglobin--metabolism
Humans
Hypoglycemic Agents--therapeutic use
Insulin Glargine
Insulin, Isophane--therapeutic use
Insulin, Long-Acting--therapeutic use
Insulin-Like Growth Factor I--metabolism
Male
Metformin--therapeutic use
Middle Aged